Pål Falck

Pål Falck has a diverse work experience in various industries and roles. Pål is currently a Board Member at Nordic Brain Tech AS and a Board Member in the Department of Pharmacy at the University of Oslo. In 2020, they served as the Chief Business Officer at Oncorena AB. Prior to that, they worked as an Equity Research Analyst Healthcare at Arctic Securities from 2018 to 2020. Pål Falck has also held positions at Pfizer, where they were a Global Scouting External R&D Innovation in Norway from 2016 to 2018, and a Medical Advisor from 2013 to 2018. Pål was the Nordic Medical Director, Oncology & Infection, and a Medical Affairs Manager at AstraZeneca from 2008 to 2013. Pål Falck's work experience also includes being a PhD student at the University of Oslo from 2004 to 2008 and a Clinical Research Associate (CRA) at SMERUD MEDICAL RESEARCH from 2002 to 2004.

Pål Falck has a diverse education history and a strong academic background. Pål began their education at the University of Oslo (UiO), where they obtained a Master's degree in Pharmacology from 1996 to 2002. Seeking further specialization, Pål attended the University of Southern California from 2001 to 2002 and earned a Master's degree in this field. Pål later returned to UiO and pursued a Doctor of Philosophy (Ph.D.) in Pharmacology, which they successfully completed from 2004 to 2008.

Pål's interest in business and management led him to pursue additional education in these fields. Pål enrolled in the BI Norwegian Business School and completed various courses as part of the Executive Master of Management program. From 2012 to 2013, they studied Economy for Decision-makers, acquiring 30 ECTS credits. Following this, from 2015 to 2016, they focused on Financial Strategy and earned an additional 30 ECTS credits. Pål continued their studies at BI Norwegian Business School from 2017 to 2018, specializing in Managerial Accounting Analysis and accumulating 30 ECTS credits. Ultimately, they completed the Executive Master of Management program in Business/Managerial Economics in 2018.

In addition to their academic achievements, Pål Falck has obtained certifications through external institutions. In February 2018, they completed the "Medical Affairs in Medicines Development" program at King's College. Around the same time, they also obtained a certification in "Medicines Development" from the IFAPP Academy.

Pål's dedication to expanding their knowledge and expertise is evident through their educational history and certifications. Pål has a strong foundation in pharmacology and has diversified their skills through their studies in business and managerial economics.